Rituximab in ANCA-Associated Vasculitis

被引：41

作者：

Hassan, Romina I. ^{[1
]}

Gaffo, Angelo L. ^{[2
,3
]}

机构：

[1] JM Ramos Mejia Hosp, Div Rheumatol, 609 Gen Urquiza St, RA-1221 Buenos Aires, DF, Argentina

[2] Birmingham VA Med Ctr, 700 19th St S, Birmingham, AL 35233 USA

[3] Univ Alabama Birmingham, Div Rheumatol & Clin Immunol, 1825 Univ Blvd,SHEL 306, Birmingham, AL 35294 USA

来源：

CURRENT RHEUMATOLOGY REPORTS | 2017年 / 19卷 / 02期

关键词：

Rituximab; Vasculitis; ANCA; Granulomatosis with polyangiitis (GPA); Microscopic polyangiitis (MPA); Eosinophilicgranulomatosiswith polyangiitis (EGPA); WEGENERS-GRANULOMATOSIS; RANDOMIZED-TRIAL; PLASMA-EXCHANGE; CYCLOPHOSPHAMIDE; INDUCTION; REMISSION; THERAPY; MAINTENANCE; MANAGEMENT; RELAPSES;

D O I：

10.1007/s11926-017-0632-1

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Purpose of Review The purpose of this review is to describe the efficacy and safety of rituximab (RTX) as a remission induction and maintenance therapy in ANCA-associated vasculitis (AAV). Recent Findings A PubMed search was carried out to track down articles published between February 2006 and February 2016. Randomized controlled trials (RCTs) that encompassed patients with AAV were included. The American College of Rheumatology (ACR) and the European League against Rheumatism (EULAR) 2014-2015 online abstracts were also reviewed whether they were RTCs or not. Ten PubMed RCTs were analyzed along with eight ACR and four EULAR abstracts. RTX was not inferior to cyclophosphamide (CYC) for remission induction in AAV; it was superior to CYC in patients with relapsing disease and superior for remission maintenance in comparison with azathioprine (AZA). Summary Rituximab is a therapeutic option to induce and maintain remission in patients with AAV.

引用

页数：8

共 50 条

[41] Infections in ANCA-associated vasculitis and lupus nephritis treated with rituximab
Temiz, Sultan Gozde
Barutcu Atas, Dilek
Alibaz Oner, Fatma
Velioglu, Arzu
Hakki Arikan, Izzet
Tuglular, Zubeyde Serhan
Direskeneli, Rafi Haner
Asicioglu, Ebru
MARMARA MEDICAL JOURNAL, 2024, 37 (03): : 268 - 273
[42] ANCA-associated vasculitis
Herrera-Darias, Sandro
Guillen-Chirinos, Gilsy
Gomez-Cerquera, Juan Manuel
MEDICINA CLINICA, 2023, 160 (10): : 467 - 467
[43] ANCA-associated vasculitis
A. Richard Kitching
Hans-Joachim Anders
Neil Basu
Elisabeth Brouwer
Jennifer Gordon
David R. Jayne
Joyce Kullman
Paul A. Lyons
Peter A. Merkel
Caroline O. S. Savage
Ulrich Specks
Renate Kain
Nature Reviews Disease Primers, 6
[44] ANCA-Associated Vasculitis
Sharma, Purva
Zonozi, Reza
Geetha, Duvuru
ADVANCES IN KIDNEY DISEASE AND HEALTH, 2024, 31 (03): : 194 - 205
[45] Induction treatment of ANCA-associated vasculitis with a single dose of rituximab
Turner-Stokes, Tabitha
Sandhu, Eleanor
Pepper, Ruth J.
Stolagiewicz, Natalie E.
Ashley, Caroline
Dinneen, Deirdre
Howie, Alexander J.
Salama, Alan D.
Burns, Aine
Little, Mark A.
RHEUMATOLOGY, 2014, 53 (08) : 1395 - 1403
[46] Severe infections in patients with ANCA-associated vasculitis treated with rituximab
Segelmark, Leo
Flores-Suarez, Luis
Mohammad, Aladdin
RHEUMATOLOGY, 2022, 61 (01) : 205 - 212
[47] Rituximab vs cyclophosphamide for cancer risk in ANCA-associated vasculitis
Mahajan, Arjun
Viola, Martin
Ellen, Jacob
Piette, Evan W.
LaChance, Avery H.
Sparks, Jeffrey A.
RHEUMATOLOGY, 2025,
[48] EFFECT OF RITUXIMAB ON MALIGNANCY RISK IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS
van Daalen, Emma Elisabeth
Rizzo, Raffaella
Kronbichler, Andreas
Wolterbeek, Ron
Bruijn, Jan Anthonie
Jayne, David
Bajema, Ingeborg
Rahmattulla, Chinar
RHEUMATOLOGY, 2017, 56
[49] The Efficacy and Safety of Rituximab in ANCA-Associated Vasculitis: A Systematic Review
Habibi, Mohammad Amin
Alesaeidi, Samira
Zahedi, Mohadeseh
Rahmani, Samin Hakimi
Piri, Seyed Mohammad
Tavakolpour, Soheil
BIOLOGY-BASEL, 2022, 11 (12):
[50] ANCA-associated vasculitis
不详
Nature Reviews Disease Primers, 6 (1)

← 1 2 3 4 5 →